Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Showing Health Information Value in a Community Network

9 de julho de 2014 atualizado por: Duke University
The purpose of this study is to determine the value of shared health information on care quality and costs when this information is used to notify care providers about concerning health events for patients cared for by a community-based network of providers.

Visão geral do estudo

Descrição detalhada

Project Abstract This three-year project will assess the costs and benefits of health information technology (HIT) in an established community-wide network of academic, private and public healthcare facilities created to share clinical information for the purpose of population-based care management of over 16,000 Medicaid beneficiaries in Durham County, North Carolina. The area of interest for this project is the impact of information-driven interventions on care quality, patient safety and healthcare costs across the diverse stakeholders participating in this collaborative partnership. In order to asses HIT value rigorously in the context of a production information system that is under continual development, we propose to conduct a randomized controlled trial. Specifically, we will randomly assign patients by family unit to either a control group or to an intervention group in which they will initially receive one of 3 information-driven interventions. The interventions include clinical alerts sent to care providers, performance feedback reports presented to clinic managers, and care reminders sent directly to patients. The content of the interventions will address "concerning" events (e.g., an emergency room encounter for asthma) and care deficiencies (e.g., delinquency on biannual mammogram) identified from the composite set of clinical data in our information system. To assess the benefits and burdens of the interventions, combinations of the 3 interventions will be sequentially introduced into the study groups over the course of the project. The analysis will compare groups receiving various combinations of interventions as well as those receiving no interventions. At baseline and at six-month intervals throughout the course of the study, we will measure emergency department encounter rates, hospitalization rates, HEDIS (Healthcare Effectiveness Data and Information Set) scores, missed appointment rates, glycated hemoglobin levels in diabetics, and patient satisfaction. Our assessment will look at the societal value of HIT as well as the value for individual stakeholders including patients, providers, payers, purchasers and policy makers. From these measures, we will assess the costs and benefits of this community-wide effort to promote interoperability of clinical data exchange in order to increase the understanding of HIT value in a community setting. In our preliminary studies, we have observed a statistically significant 3-fold reduction in repeat ED (Emergency Department) encounter rates using email alerts alone. The approach used in this project is able to be generalized across geographic areas and healthcare settings and can, therefore, serve to promote the dissemination of HIT to other communities.

Tipo de estudo

Intervencional

Inscrição (Real)

20108

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • North Carolina
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University Medical Center

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Enrollment in the Community Care of North Carolina Medicaid program in Durham County North Carolina

Exclusion Criteria:

-

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição fatorial
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: 1
electronic mail notifications to care managers about sentinel health events
computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
Outros nomes:
  • Decision support engine is called SEBASTIAN
Experimental: 2
feedback reports with notifications to clinic managers about sentinel health events
computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
Outros nomes:
  • Decision support engine is called SEBASTIAN
Experimental: 3
letters to patients with notifications about sentinel health events
computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
Outros nomes:
  • Decision support engine is called SEBASTIAN
Sem intervenção: 4
electronic mail notifications to care managers about sentinel health events -- generated but withheld
Sem intervenção: 5
feedback reports with notifications to clinic managers about sentinel health events -- generated but withheld
Sem intervenção: 6
letters to patients with notifications about sentinel health events -- generated but withheld

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Prazo
Emergency department utilization rates and hospitalization rates
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

Medidas de resultados secundários

Medida de resultado
Prazo
ED encounter rates for low severity conditions
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
ED encounter rates for asthma
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
ED encounter rates for diabetes
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Hospitalization rates
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Hospitalization rates for asthma (also PQI)
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Hospitalization rates for diabetes (also PQI)
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Glycemic control (hemoglobin A1c)
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Medication contraindications
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
HEDIS - Preventive services
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
HEDIS - # WCC visits
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
AHRQ Prevention Quality Indicators
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
HEDIS - Asthma and diabetes
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
# of messages triggered for health risks
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
# of messages triggered for barriers to care
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Missed appointment rates
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Primary care appointment rates
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
F/U rates post-partum
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Patient satisfaction instruments (CHAPS)
Prazo: at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced.
at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced.
EuroQoL
Prazo: at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced.
at 6 to 9 months after the intervention has been introduced and then at 3 to 6-month intervals as the intervention is sequentially enhanced.
Provider opinion surveys
Prazo: At conclusion of study
At conclusion of study
Costs of ED utilization for all causes
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Costs of ED use for asthma
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Costs of ED use for diabetes
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Costs of ED use for low severity visits
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Hospitalization costs for all causes
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Hospitalization costs for asthma
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Hospitalization costs for diabetes
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Reimbursement for labs+other ancillary services
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
Primary care reimbursement
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
ED rates for recurrent ED encounters
Prazo: at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.
at 9 months after the intervention has been introduced and then at 6-month intervals as the intervention is sequentially enhanced.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: David F Lobach, MD, PhD, Duke University

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo

1 de agosto de 2006

Conclusão Primária (Real)

1 de julho de 2008

Conclusão do estudo (Real)

1 de agosto de 2008

Datas de inscrição no estudo

Enviado pela primeira vez

16 de agosto de 2006

Enviado pela primeira vez que atendeu aos critérios de CQ

16 de agosto de 2006

Primeira postagem (Estimativa)

18 de agosto de 2006

Atualizações de registro de estudo

Última Atualização Postada (Estimativa)

11 de julho de 2014

Última atualização enviada que atendeu aos critérios de controle de qualidade

9 de julho de 2014

Última verificação

1 de dezembro de 2012

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • Pro00006833
  • R01HS015057 (Concessão/Contrato da AHRQ dos EUA)

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever